Pfizer Inc.’s deal aspirations are probably bigger than Hospira Inc.

Buying the injectable drugmaker doesn’t give Pfizer the innovative products and lower tax rate that the $208 billion pharmaceutical giant was seeking in its failed bid for AstraZeneca Plc last year. Pfizer’s $17 billion bill for Hospira is just a fraction of the almost $120 billion it was willing to pay for AstraZeneca, so the New York-based company has plenty of capacity to go after more targets. Chief Executive Officer Ian Read said Pfizer continues to look at opportunities.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.